Here is CNBC-TV18’s Archi Damania’s comments on how the pharma sector has performed.

The underperformers since January

Panacea Biotec                        -42%

Wockhardt                                -63%

Biocon                                     -71%

The outperformers since January

Sun Pharma                              +30%

Lupin                                        +17%

GlaxoPharma                            +16%

Both Lupin and Sun Pharma are fully integrated companies. They have captured niche generics opportunity in the regulated markets.

Lupin is looking to enter contract manufacturing through acquisition of Rubamin. It has successfully integrated acquisitions like Kyowa. The company is entering Europe and South African markets through acquisitions and it is looking at one more acquisitions in Japan.

Sun Pharma is a strong brand in the domestic market. The company is expanding through organic and inorganic routes. It is pursuing the acquisition of Taro. The company has a history of buying distressed companies and successfully turning them around. It also has a track record of delivering consistent growth and maintaining profitability.

Citi sees Sun Pharma’s target at Rs 1,659 which is 12% upside from the current levels.

GSK Pharma expects to launch 5 patented products over CY08–10. It launched Tykerb in Q2.